Leukemia Clinical Trials in Ohio

Showing 1821-1840 of 1,856 trials

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

NCT00064584

This is the first study of the drug CT53518 when given to humans. The purpose of this study is to determine the highest dose of CT53518 that can safely be given to patients with Acute Myelogenous Leukemia (AML) and to identify the side effects associated with taking the drug. The study will evaluate how CT53518 is absorbed, broken down, and eliminated by the body. Additionally, the study will evaluate the effects of the drug on a specific type of cell in bone marrow and blood, known as a blast.

Acute Myelogenous LeukemiaMyelodysplastic Syndrome

Millennium Pharmaceuticals, Inc.60 participantsStarted May 2002

Los Angeles, California, United States • Boston, Massachusetts, United States • New York, New York, United States +2 more locations

COMPLETEDPhase 332 miles

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

NCT00054795

The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability to think for a longer time compared to patients treated with whole brain radiation therapy alone.

Brain NeoplasmsCarcinoma, Non-Small-Cell LungMetastases, Neoplasm

Pharmacyclics LLC.550 participants

Phoenix, Arizona, United States • Fort Smith, Arkansas, United States • Little Rock, Arkansas, United States +89 more locations

PreviousPage 92 of 93Next

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Leukemia Trials in Other Cities

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis

A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer

Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer

CPG 7909 Injection in Non-Small Cell Lung Cancer

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide

Other Conditions in Ohio